DickSIM
Prima o poi....ci becco!
Se avesse capito non sarebbe poi cosi' male ma lo perdoniamo solo dopo un pellegrinaggio nitrico
in ginocchio.............???????????
NicOx : Garufi ... e la Rivoluzione Pharma (2 lettori)
- Creatore Discussione Yesod
- Data di Inizio
- Stato
in ginocchio.............???????????
doctor NO
NO nel DNA
Goran Ando che collabora con noi è anche nel management di novonordisk ma quelli sono specializzati nella cura del diabetepenso che sia stato già fatto notare............ se cosi nn fosse meglio!
dicevo....... pare sia nato un'asse FRANCIA-ITALIA-OLANDA
abbiamo DSM per la preduzione......... e ABN AMRO nella finanza!
la pista Europea parrebbe quella più forte........
a tal proposito tirerei fuori
http://www.novonordisk.com/
DickSIM
Prima o poi....ci becco!
Goran Ando che collabora con noi è anche nel management di novonordisk ma quelli sono specializzati nella cura del diabete
entrano con noi..............nel mercato nsaid
e gli diamo le statinelle antidiabetiche.......... meglio di cosi! 
DickSIM
Prima o poi....ci becco!
farmacia10
el pueblo unido...
per chi sbaglia target in ginocchio e sui carboni ardenti
oppure berra' una mia pozione a sorpresa
DickSIM
Prima o poi....ci becco!
Pfizer Suspends Late-Stage Trial Of Pancreatic Cancer Drug Axitinib - Update
Fri. January 30, 2009; Posted: 06:13 PM
RTTNews) - Drug maker Pfizer Inc. (PFE | Quote | Chart | News | PowerRating), Friday said it has discontinued a late-stage trial of its investigational agent axitinib for advanced pancreatic cancer, as no further improvement in the primary endpoint of survival was seen.
The development is yet another blow for Pfizerthat is presently undergoing a tough time with a slump in sales and lower profit.
Mace Rothenberg, Senior Vice President, Clinical Development and Medical Affairs, Pfizer's Oncology Business Unit said, "These results were disappointing, given the trend towards prolonged survival seen in a Phase II study of axitinib in this extremely difficult-to-treat patient population."
Based on an interim analysis, an independent Data Safety Monitoring Board found no evidence of improvement in the primary endpoint of survival in patients treated with axitinib and gemcitabine, compared to gemcitabine alone, the current standard of care for patients with advanced pancreatic cancer.
Pfizer notified all clinical trial investigators involved in the study and regulatory agencies of these interim findings and recommended that patients discontinue treatment with axitinib.
Axitinib is an oral and selective inhibitor of VEGF receptors 1, 2 and 3. It is an investigational agent and has not yet been approved by the FDA or other global regulatory agencies.
Pfizer said it will continue investigation of axitinib in renal cell carcinoma where it is currently in phase III study as a 2nd line treatment.
Earlier this week, Pfizer reported a 90% drop in its fourth quarter profit over last year, hurt by a hefty charge on legal settlement and lower sales. The company also provided financial outlook for the full year 2009, below current analysts' estimates.
In addition, Pfizer said it would implement a new cost-reduction initiative that will drive a lower, more variable cost structure to achieve anticipated incremental savings of about $3 billion and net savings of $2 billion. The program will be substantially complete by the end of 2010, with the full savings to be realized by the end of 2011.
As part of this cost-reduction initiative, Pfizer plans to reduce its workforce by about 10%, spanning sales, manufacturing, research and development, and administrative organizations. The company also plans to reduce the number of manufacturing sites to 41 from 46, as well as reduce its facilities square footage by about 15%.
Separately, Pfizer said it has agreed to buy Wyeth in a cash-and-stock deal currently valued at $50.19 per share, aggregating about $68 billion.
Wyeth shareholders under the deal will receive $33 in cash and 0.985 of a share of Pfizer common stockfor each Wyeth share held, subject to terms of the merger agreement. Based on the closing price of Pfizer stock on Friday, the stock component is valued at $17.19 per share.
The transaction is expected to close at the end of third quarter or during the fourth quarter 2009.
Fri. January 30, 2009; Posted: 06:13 PM
RTTNews) - Drug maker Pfizer Inc. (PFE | Quote | Chart | News | PowerRating), Friday said it has discontinued a late-stage trial of its investigational agent axitinib for advanced pancreatic cancer, as no further improvement in the primary endpoint of survival was seen.
The development is yet another blow for Pfizerthat is presently undergoing a tough time with a slump in sales and lower profit.
Mace Rothenberg, Senior Vice President, Clinical Development and Medical Affairs, Pfizer's Oncology Business Unit said, "These results were disappointing, given the trend towards prolonged survival seen in a Phase II study of axitinib in this extremely difficult-to-treat patient population."
Based on an interim analysis, an independent Data Safety Monitoring Board found no evidence of improvement in the primary endpoint of survival in patients treated with axitinib and gemcitabine, compared to gemcitabine alone, the current standard of care for patients with advanced pancreatic cancer.
Pfizer notified all clinical trial investigators involved in the study and regulatory agencies of these interim findings and recommended that patients discontinue treatment with axitinib.
Axitinib is an oral and selective inhibitor of VEGF receptors 1, 2 and 3. It is an investigational agent and has not yet been approved by the FDA or other global regulatory agencies.
Pfizer said it will continue investigation of axitinib in renal cell carcinoma where it is currently in phase III study as a 2nd line treatment.
Earlier this week, Pfizer reported a 90% drop in its fourth quarter profit over last year, hurt by a hefty charge on legal settlement and lower sales. The company also provided financial outlook for the full year 2009, below current analysts' estimates.
In addition, Pfizer said it would implement a new cost-reduction initiative that will drive a lower, more variable cost structure to achieve anticipated incremental savings of about $3 billion and net savings of $2 billion. The program will be substantially complete by the end of 2010, with the full savings to be realized by the end of 2011.
As part of this cost-reduction initiative, Pfizer plans to reduce its workforce by about 10%, spanning sales, manufacturing, research and development, and administrative organizations. The company also plans to reduce the number of manufacturing sites to 41 from 46, as well as reduce its facilities square footage by about 15%.
Separately, Pfizer said it has agreed to buy Wyeth in a cash-and-stock deal currently valued at $50.19 per share, aggregating about $68 billion.
Wyeth shareholders under the deal will receive $33 in cash and 0.985 of a share of Pfizer common stockfor each Wyeth share held, subject to terms of the merger agreement. Based on the closing price of Pfizer stock on Friday, the stock component is valued at $17.19 per share.
The transaction is expected to close at the end of third quarter or during the fourth quarter 2009.
Netzach
Forumer storico
per chi sbaglia target in ginocchio e sui carboni ardenti
Ecco di cosa avranno bisogno coloro che sbagliano target ...
DickSIM
Prima o poi....ci becco!
Merck seeks new medicine uses, cutting jobs again
January 30, 2009 3:49 PM ET
All Associated Press news
WHITEHOUSE STATION, N.J. (AP) - Merck & Co., a Dow component and the world's No. 8 drugmaker by revenue, reports earnings for the fourth quarter on Tuesday morning. The following is a summary of key developments and analyst opinion related to the period.
OVERVIEW: Merck is in the process of eliminating about 7,200 jobs, or nearly 13 percent of its workforce, as sales of some key products have been flat or slumping, including blockbuster osteoporosis treatment Fosamax, which got generic competition early last year.
It's also been plagued by a variety of production problems with its vaccines, troubles that have limited supplies and reduced revenue. Shingles vaccine Zostavax remains back-ordered, although many orders were filled in December, while hepatitis A vaccine Vaqta is only being shipped for children. It is expected to become available for adults in the second quarter. Shortages hit hepatitis B vaccine Recombivax in January, due to the need to upgrade some manufacturing equipment, with only a version for children available now.
Sales of the cholesterol drugs Merck jointly sells with partner Schering-Plough Corp. have been hammered for a year by reports questioning their efficacy and safety.
But earlier this month, the Food and Drug Administration said patients should not stop taking Vytorin, Zetia or other cholesterol-lowering drugs, based on its review of a controversial study that hammered Vytorin and Zetia sales.
In December, Merck ended its partnership with Dynavax Technologies Corp. on an experimental hepatitis B vaccine that ran into safety problems.
BY THE NUMBERS: Analysts polled by Thomson Financial expect, on average, earnings per share of 74 cents and revenue of $5.98 billion. In the year-earlier period, Merck posted a net loss of 75 cents per share, mainly due to a $4.85 billion charge to settle thousands of lawsuits over withdrawn painkiller Vioxx; revenue that quarter was $6.24 billion.
In the third quarter, earnings per share fell to 51 cents on a charge for restructuring, from 70 cents in the 2007 period.
ANALYST TAKE: Deutsche Bank analyst Barbara Ryan, who has a "Buy" rating on Merck, expects fourth-quarter revenue to be down about 7 percent because of slight declines in sales of vaccines, cholesterol drugs and asthma drug Singulair, plus Fosamax generic competition and unfavorable currency exchange rates, which hurt all major U.S. drugmakers in the quarter. But with the planned job cuts, she believes Merck can increase earnings per share in the mid-single digits through 2011. She writes that the management team seems committed to creating a company with a lower and more flexible cost structure.
Credit Suisse analyst Catherine Arnold sees Merck cutting marketing and administrative costs by a few hundred million dollars in 2009, boosting research spending by $100,000 or more and facing a slightly higher tax rate.
WHAT'S AHEAD: Merck has asked federal regulators to approve use in males of Gardasil, its vaccine against the human papillomavirus, which causes cervical and other sexually transmitted cancers and genital warts. Gardasil was launched in 2006 for girls and young women. Last June, the Food and Drug Administration rejected its use for older women, but in January it asked for more data on that issue. Merck also is seeking FDA approval to market its HIV drug Isentress in new patients, not just ones already treated with other medicines.
January 30, 2009 3:49 PM ET
All Associated Press news
WHITEHOUSE STATION, N.J. (AP) - Merck & Co., a Dow component and the world's No. 8 drugmaker by revenue, reports earnings for the fourth quarter on Tuesday morning. The following is a summary of key developments and analyst opinion related to the period.
OVERVIEW: Merck is in the process of eliminating about 7,200 jobs, or nearly 13 percent of its workforce, as sales of some key products have been flat or slumping, including blockbuster osteoporosis treatment Fosamax, which got generic competition early last year.
It's also been plagued by a variety of production problems with its vaccines, troubles that have limited supplies and reduced revenue. Shingles vaccine Zostavax remains back-ordered, although many orders were filled in December, while hepatitis A vaccine Vaqta is only being shipped for children. It is expected to become available for adults in the second quarter. Shortages hit hepatitis B vaccine Recombivax in January, due to the need to upgrade some manufacturing equipment, with only a version for children available now.
Sales of the cholesterol drugs Merck jointly sells with partner Schering-Plough Corp. have been hammered for a year by reports questioning their efficacy and safety.
But earlier this month, the Food and Drug Administration said patients should not stop taking Vytorin, Zetia or other cholesterol-lowering drugs, based on its review of a controversial study that hammered Vytorin and Zetia sales.
In December, Merck ended its partnership with Dynavax Technologies Corp. on an experimental hepatitis B vaccine that ran into safety problems.
BY THE NUMBERS: Analysts polled by Thomson Financial expect, on average, earnings per share of 74 cents and revenue of $5.98 billion. In the year-earlier period, Merck posted a net loss of 75 cents per share, mainly due to a $4.85 billion charge to settle thousands of lawsuits over withdrawn painkiller Vioxx; revenue that quarter was $6.24 billion.
In the third quarter, earnings per share fell to 51 cents on a charge for restructuring, from 70 cents in the 2007 period.
ANALYST TAKE: Deutsche Bank analyst Barbara Ryan, who has a "Buy" rating on Merck, expects fourth-quarter revenue to be down about 7 percent because of slight declines in sales of vaccines, cholesterol drugs and asthma drug Singulair, plus Fosamax generic competition and unfavorable currency exchange rates, which hurt all major U.S. drugmakers in the quarter. But with the planned job cuts, she believes Merck can increase earnings per share in the mid-single digits through 2011. She writes that the management team seems committed to creating a company with a lower and more flexible cost structure.
Credit Suisse analyst Catherine Arnold sees Merck cutting marketing and administrative costs by a few hundred million dollars in 2009, boosting research spending by $100,000 or more and facing a slightly higher tax rate.
WHAT'S AHEAD: Merck has asked federal regulators to approve use in males of Gardasil, its vaccine against the human papillomavirus, which causes cervical and other sexually transmitted cancers and genital warts. Gardasil was launched in 2006 for girls and young women. Last June, the Food and Drug Administration rejected its use for older women, but in January it asked for more data on that issue. Merck also is seeking FDA approval to market its HIV drug Isentress in new patients, not just ones already treated with other medicines.
- Stato